

Supplementary material

Wybraniec MT, Maciąg A, Miśkowiec D et al. Antiarrhythmic drugs for pharmacological cardioversion of atrial fibrillation and gender differences: Insights from CANT II Study. Kardiol Pol. 2023.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1 Univariable analysis of different predictors of successful pharmacological cardioversion in women and men

| Variable | OR | 95% CI | P-value |
|---|-------|-------------|---------|
| Women | | | |
| Age, per 1 year | 0.973 | 0.955–0.992 | 0.005 |
| EHRA class, per 1 class | 0.651 | 0.496–0.853 | 0.002 |
| Arterial hypertension | 0.605 | 0.369–0.991 | 0.046 |
| Diabetes mellitus | 0.673 | 0.439–1.032 | 0.07 |
| Obesity | 0.852 | 0.734–1.424 | 0.31 |
| Coronary artery disease | 1.027 | 0.674–1.566 | 0.90 |
| White blood cells count, per 1000/ μ l | 0.961 | 0.880–1.050 | 0.38 |
| Hemoglobin level, per 1 g/dl | 0.980 | 0.856–1.121 | 0.76 |
| Potassium level, per 1 mmol/l | 0.591 | 0.383–0.913 | 0.02 |
| AF episode duration >7 days | 0.084 | 0.042–0.170 | <0.001 |
| eGFR, per a 1 ml/min increase | 1.012 | 1.002–1.023 | 0.02 |
| LVEF < 50% | 0.543 | 0.300–0.984 | 0.04 |
| CHA ₂ DS ₂ -VASc score, per 1 point | 0.830 | 0.729–0.945 | 0.005 |
| History of stroke/TIA | 1.436 | 0.664–3.108 | 0.36 |
| Structural heart disease | 0.794 | 0.542–1.163 | 0.24 |
| Left atrial diameter, per 1 mm | 0.939 | 0.899–0.980 | 0.004 |
| History of PVI | 0.822 | 0.410–1.647 | 0.58 |
| IV potassium infusion | 1.662 | 1.156–2.392 | 0.006 |
| Beta-blocker | 1.338 | 0.937–1.912 | 0.11 |
| Amiodarone ^a vs. other AAD | 0.515 | 0.364–0.729 | <0.001 |
| Antazoline ^a vs. other AAD | 1.054 | 0.744–1.493 | 0.77 |

| | | | |
|---|-------|-------------|--------|
| Propafenone ^a vs. other AAD | 1.021 | 0.672–1.551 | 0.92 |
| Men | | | |
| Age, per 1 year | 1.003 | 0.991–1.016 | 0.64 |
| EHRA class, per 1 class | 0.656 | 0.505–0.854 | 0.002 |
| Arterial hypertension | 1.046 | 0.674–1.626 | 0.84 |
| Diabetes mellitus | 1.285 | 0.831–1.987 | 0.26 |
| Coronary artery disease | 2.137 | 1.481–3.083 | <0.001 |
| White blood cells count, per 1000/ μ l | 1.016 | 0.942–1.096 | 0.68 |
| Hemoglobin level, per 1 g/dl | 0.885 | 0.773–1.013 | 0.08 |
| Potassium level, per 1 mmol/l | 0.731 | 0.490–1.090 | 0.12 |
| AF episode duration >7 days | 0.077 | 0.036–0.165 | <0.001 |
| eGFR, per a 1 ml/min increase | 1.008 | 0.995–1.020 | 0.23 |
| LVEF <50% | 0.732 | 0.437–1.227 | 0.24 |
| CHA ₂ DS ₂ -VASc score, per 1 point | 1.055 | 0.926–1.201 | 0.42 |
| History of stroke/TIA | 2.036 | 0.749–5.537 | 0.16 |
| Structural heart disease | 1.615 | 1.167–2.233 | 0.004 |
| Left atrial diameter, per 1 mm | 0.945 | 0.907–0.984 | 0.006 |
| History of PVI | 1.879 | 1.063–3.323 | 0.03 |
| Intravenous potassium infusion | 1.619 | 1.153–2.272 | 0.005 |
| Beta-blocker | 0.800 | 0.577–1.110 | 0.18 |
| Amiodarone ^a vs. other AAD | 0.644 | 0.463–0.896 | 0.009 |
| Antazoline ^a vs. other AAD | 1.277 | 0.904–1.803 | 0.17 |
| Propafenone ^a vs. other AAD | 0.561 | 0.385–0.818 | 0.002 |

^aRelative to the whole population of women treated with antiarrhythmic agents

Abbreviations: AAD, antiarrhythmic drugs; AF, atrial fibrillation; CI, confidence interval; eGFR, estimated glomerular filtration rate; EHRA, European Heart Rhythm Association classification; LVEF, left ventricular ejection fraction; OR, odds ratio; PVI, pulmonary vein isolation; TIA, transient ischemic attack